Literature DB >> 22172931

Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: a reevaluation in East Asian populations.

Kensuke Utsunomiya1, Takahiro Shinkai, Shinichi Sakata, Kenji Yamada, Hsin-I Chen, Vincenzo De Luca, Rudi Hwang, Osamu Ohmori, Jun Nakamura.   

Abstract

The dopamine D3 receptor gene (DRD3) is considered being one of the candidate genes contributing to the development of tardive dyskinesia (TD). In a recent meta-analysis with mixed ethnicities, only a barely positive association was found between the functional DRD3 Ser9Gly polymorphism and TD in patients with schizophrenia (OR=1.17; 95% CI: 1.01-1.37; p=0.041). To further evaluate the controversial association between the polymorphism and TD using only Japanese subjects, we tested the association in a case-control design. We also conducted a meta-analysis including 8 studies with 3 East Asian populations (Japanese, Chinese, and Korean). In our Japanese case-control sample (43 with TD/157 without TD), we found no association between the DRD3 Ser9Gly polymorphism in schizophrenia and TD (genotype: p=0.92; allele: p=1.00). Furthermore, no significant difference in the mean AIMS score among the three genotypic groups was observed in our sample. The meta-analysis comprising 1291 East Asian subjects also showed no association between the polymorphism and TD; the Mantel-Haenszel pooled OR for TD among carriers of the DRD3 Ser9Gly of the eight Asian studies was 0.94 (95% CI: 0.78-1.12). Overall, our results suggest that the DRD3 Ser9Gly polymorphism may not confer susceptibility to TD in East Asian populations. Given that the Ser9Gly variant may play a putative role in the DRD3 function, further studies on the DRD3 are warranted.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22172931     DOI: 10.1016/j.neulet.2011.11.050

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

Review 1.  Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects.

Authors:  George Anderson; Michael Maes
Journal:  Metab Brain Dis       Date:  2012-04-25       Impact factor: 3.584

Review 2.  Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder?

Authors:  Changsu Han; Chi-Un Pae
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

3.  Dopaminergic gene polymorphisms and cognitive function in a north Indian schizophrenia cohort.

Authors:  Prachi Kukshal; Venkat Chowdari Kodavali; Vibhuti Srivastava; Joel Wood; Lora McClain; Triptish Bhatia; A M Bhagwat; Smita Neelkanth Deshpande; Vishwajit Laxmikant Nimgaonkar; B K Thelma
Journal:  J Psychiatr Res       Date:  2013-08-08       Impact factor: 4.791

Review 4.  The genetics of drug-related movement disorders, an umbrella review of meta-analyses.

Authors:  Nadine C van der Burg; Asmar F Y Al Hadithy; Peter N van Harten; Jim van Os; P Roberto Bakker
Journal:  Mol Psychiatry       Date:  2020-02-04       Impact factor: 15.992

Review 5.  Treatment of neurolept-induced tardive dyskinesia.

Authors:  Stacey K Jankelowitz
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-16       Impact factor: 2.570

Review 6.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

7.  No association between the Ser9Gly polymorphism of the dopamine receptor D3 gene and schizophrenia: a meta-analysis of family-based association studies.

Authors:  Xiao-Na Li; Ji-Long Zheng; Xiao-Han Wei; Bao-Jie Wang; Jun Yao
Journal:  BMC Med Genet       Date:  2020-04-21       Impact factor: 2.103

Review 8.  Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Authors:  Evangelia Eirini Tsermpini; Sara Redenšek; Vita Dolžan
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

9.  New Insight into the human genetic diversity in North African populations by genotyping of SNPs in DRD3, CSMD1 and NRG1 genes.

Authors:  Souhir Mestiri; Sami Boussetta; Andrew J Pakstis; Sarra El Kamel; Amel Ben Ammar El Gaaied; Kenneth K Kidd; Lotfi Cherni
Journal:  Mol Genet Genomic Med       Date:  2022-02-07       Impact factor: 2.183

10.  No association between dopamine D3 receptor gene Ser9Gly polymorphism (rs6280) and risk of schizophrenia: an updated meta-analysis.

Authors:  Xing-Ling Qi; Jin-Feng Xuan; Jia-Xin Xing; Bao-Jie Wang; Jun Yao
Journal:  Neuropsychiatr Dis Treat       Date:  2017-11-23       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.